Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CODA +5.8%
Other news:
- ELMT +48.2% (lands $450 mln Department of War investment; secures up to $2 bln stockpile agreement; to deploy $450 mln DoW commitment to expand U.S., allied tungsten supply chain)
- BMM +21.2% (secures up to $175 mln investment framework to restart Nevada tungsten complex)
- CRBP +9.4% (CANYON-1 obesity study of CRB-913 showed 5% mean weight loss at 60 mg by Week 12)
- SRRK +9% (receives FDA approval for ISEMBYLD in spinal muscular atrophy; U.S. launch underway)
- DFTX +8% (Phase 3 Panorama study of DT120 ODT in GAD met primary, all key secondary endpoints)
- BNTX +7% (BioNTech and OncoC4 present updated data showing gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients)
- ARMP +6.7% (Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02)
- TLX +6.6% (FDA approval for Pixclara brain cancer imaging drug)
- CRWD +5.4% (files for 2,118,022 share common stock offering by selling stockholder)
- EVCM +5.4% (boosts buyback authorization by $25 mln, extends program through Dec. 31, 2027)
- SMMT +4.4% (partner Akeso reports ivonescimab OS win over pembrolizumab in Phase III NSCLC study)
- VG +3.7% (signs 20-year LNG supply deal with China Gas for 0.5 MTPA starting 2030)
- GSK +3.6% (Jideytro posts 94% response rate in registrational first-line ROS1-positive lung cancer trial; Ris-Rez cuts risk of death 54% in Phase III relapsed small cell lung cancer trial)
- TMQ +3.1% (closes $35.6 mln strategic equity investment by the U.S. Department of War)
- CATX +2.3% (clinical collaboration and supply agreement with Merck (MRK) to evaluate [212Pb]PSV359 in combination with Keytruda (Pembrolizumab) in FAP-a positive solid tumors)
- FRO +2.1% (declares one time special dividend of $0.80/share after sale of two VLLCs)
- AZN +1.6% (announces update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib; did not meet primary objective; says TAGRISSO showed 8-year survival benefit in Phase III ADAURA trial; ENHERTU met Phase III PFS endpoint in first-line HER2-mutant NSCLC; misses primary endpoint in Phase III first-line breast cancer trial)
- QSR +1.5% (announces that the Toronto Stock Exchange accepted notice of its intention to renew its normal course issuer bid, which is being conducted in furtherance of the board-approved share repurchase authorization allowing for repurchase up to 1.0 bln of common shares)
- TAK +1.4% (FDA accepts zasocitinib NDA under Priority Review for plaque psoriasis)
- WHWK +1.2% (presents real-world analyses supporting PTK7 as a durable ADC target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026)
- JNJ +1.1% (RYBREVANT plus chemotherapy shows final OS benefit in Phase III PAPILLON study)